Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Address: Csorsz ut 49-51 H-1124 Budapest,Hungary
Tel: +36 1 577 8200
Web: http://www.astellas.com/worldwide.html
Astellas Pharma Europe the world’s 20 largest pharmaceutical company, belonging to 15 thousand employees worldwide Astellas Pharma Inc. subsidiary. As a young and forward-looking company Astellas aims to improve the quality of life for people around the world, innovative and reliable pharmaceutical products, by providing products.
In 2005, Yamanouchi and Fujisawa merger created Astellas remains committed to the class of the first (‘first-in-class’), and class best (‘best-in-class’) products developed for the key therapeutic areas by combining high R & D and marketing opportunities in the pharmaceutical world market continued growth.
In October 2006, Astellas has launched a company called Vision 2015 management strategy. Declared goal is to világelsőkké within that category (GAL) to become a number of therapeutic areas where further innovation of the patients currently unmet needs can be met. The company’s vision is an integral part in 2008, launched a wide-ranging Changing TOMORROW ™ (‘Change your tomorrow’) campaign, which displays the company’s ability to create a brighter future stakeholders, especially patients.
Significant, ongoing investments in research and development will further strengthen research-based Astellas pharmaceutical company capacity by providing effective medicines for patients worldwide, and continues to doctors and trusted partner of network deployment.
In Europe the main strengths of the Astella organ transplantation, urology, dermatology and anti-infective agents and the therapeutic areas of pain prevail. In addition, Astellas aims to develop a gyógyszerportfóliót the needs of cancer patients.
Astellas Pharma Europe Ltd. is based in Staines near London, and operates sales subsidiaries throughout Europe and the CIS states and South Africa. Astellas Pharma International, as well as licensors and distributors, the company responsible for the Middle East and Africa sales as well.
Geninax® : an oral new-type quinolone antibacterial agent
Celecox® : the selective COX-2 lnhibitor
Lipitor® : a treatment for hypercholesterolemia
Micardis® : a treatment for hypertension
Gaster® : a treatment for peptic ulcers and gastritis
Luvox® : an antidepressant
Myslee® : a hypnotic
Cefzon® : an oral cephalosporin
Seroquel® : an antipsychotic agent
Dorner® : a treatment for chronic arterial occlusion
Nasea® : a 5-HT3 (receptor) antagonist
Targocid® : a glycopeptide antibiotic
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
See our Cookie Privacy Policy Here